|
| |
| |
Lee E. Babiss, Ph.D., is vice president of Preclinical Research and Development for Roche, in Nutley, New Jersey, where he develops and directs oncology and metabolic diseases research strategy for the site. In addition, Babiss is a member of the International Research Management Team, which develops the company’s global research strategy and is the Chair of the Roche Biomarker Leadership Team, which oversees a cross-divisional effort within the company’s pharmaceuticals and diagnostics divisions aimed at developing and implementing a biomarker strategy.
Prior to Roche, Babiss was vice president of Biological Sciences and Genetics at Glaxo Wellcome where he focused on the development of antisense technology and cancer therapeutics, headed the Department of Molecular Cell Biology, and played a key role developing and implementing the Cell Cycle Program. Babiss also served as a member of the U.S. Research Senior Management Team, which formulated and implemented Glaxo’s U.S. research strategy and was involved in creating the Glaxo Wellcome Corporate Genetic Strategy, which led to the creation of the company’s Genetics Division.
Babiss attended graduate school at Columbia University, College of Physicians and Surgeons, in New York, where he earned his Ph.D. in Microbiology in 1982 studying DNA tumor viruses. He then began his postdoctoral career at the Rockefeller University in New York studying molecular regulation of hepatocyte gene expression and was later promoted to assistant professor in Cell Biology, studying adenovirus genetics.
An author on more than 60 publications, Babiss currently serves on the board of the Biotechnology Industry Organization (BIO), the board of the Center for Advanced Biotechnology and Medicine at UMDNJ, the R&D Council of New Jersey , the Finance Board of the American Society of Microbiology and on the Scientific Advisory Board of CuraGen Corporation. |
| |
| Back to Editorial |
| |
| |
|
|
|
|
| |
